Liven Pharma Limited has transmitted its annual report for the year ended June 30, 2026, detailing its financial performance and strategic outlook amidst challenging economic conditions.
- The company recorded a turnover of PKR 105.807M, down from PKR 127.272M in 2025.
- Gross profit improved to PKR 26.646M (2025: PKR 17.959M), with a gross margin increase to 25.2%.
- Operating loss narrowed to PKR 77.140M, significantly better than the previous year's loss of PKR 490.902M, which included a one-off listing expense.
- Loss After Tax amounted to PKR 31.139M, compared to PKR 584.460M in 2025.
- Earnings Per Share (EPS) improved to PKR -0.28 from PKR -7.11 (restated) last year.
- Total equity increased to PKR 985.458M, driven by a rights issue and a revaluation surplus of PKR 188.911M.
- The company continues to focus on international expansion and diversification into higher-value pharmaceutical segments.
- No dividends were declared due to financial headwinds, but future growth prospects remain optimistic.